#LaxmiOrganics Q1 2023 Concall Highlights

Like & retweet for better reach !

1. Despite the market volatility and the inflationary pressure seen across the globe the Speciality Intermediates (SI) business saw growth both in the exports & in the contribution margins.
2. Commissioned a new plant for SI supplies to an agrochemical major. Most of this capacity is already contracted.

3. The AI business saw QoQ improvement in EBITDA Margins and exports also grew very well. Almost 40% of the revenues of the company came from exports in the Q1FY23.
4. The company optimizes procurement between imports and local supplies to support the margin expansion in the AI business that was aided also by the softening of petrochemicals and acetic acid prices internationally.

5. The quarterly EBITDA at 104 Crores resulted in an
improved EBITDA Margin at 14% an increase of 29 Crores viz a viz Q4FY22. This was due to better contribution margins in both businesses and an optimizing of the SI product mix

6. Given that the revenue of Q1FY23 at 759 Crores was about 14% lower than Q4FY22.
On an annual basis the revenue of Q1FY23 was flat as compared to that of Q1FY22 which was 741 Crores.

7. This fiscal the company will commence the fluoro speciality unit. Almost all the civil and infrastructure work is completed at Lote Parshuram site and packaging
and dispatching from Italy is also on track.

8. The heat wave Europe is facing and has slowed down some of the dismantling work. Since the conditions are not conducive for the workers to work, a dedicated team from the company's side has been established at the site to
put in place measures that will reduce the impact of this disruption.

9. After completion of the fluoro speciality business the company will continue to invest in the debottlenecking investments for the AI business.The SI business capex is continuing smoothly and the company
is on track to commission yet another new plant in Q3FY23.

10. Overall the company has been able to develop core capabilities to execute organic capex of 350 crores annually.

11. In the Fluoro specialities segment the company is getting inquiries in all three product segments-
Pharma, Agro and industrial. Industrial- is that segment in which the product goes into coatings, inks and adhesives. So these are new products that are required by the company’s existing customers at some point in their new product life cycle.
12. Miteni’s value proposition- Their starting points were chlorine and toluene and then hydrofluoride (HF) was one of the steps they performed in their value chain and Laxmi is looking to replicate that in India.
13. More than 90% of the capex will go towards speciality businesses going forward.

14. Annual capex of 350 crores. There will be some debt that the company will take as an organization because it will improve their working capital.
The company doesn't want to be just reliant on the internal accruals.

15. Many of Laxmi’s products find application in a diverse set of markets so given Laxmi’s global supply chain the company is being able to move products across different geographies as well so the
Acetyl segment had a slight increase in its export ratio in the last quarter primarily because the company found some other markets being more fruitful than others.

16. Current EBITDA Margins are 12%. Fluoro speciality segment will increase the EBITDA Margins going forward.
17. Miteni used to do only fine and speciality chemicals. Laxmi is not looking at the entire refrigerant space as a business. Within the fine and speciality chemicals the products that Miteni would manufacture none of those products were produced in India at that time.
Laxmi’s intention is to start off with 8-10 products which sets the baseline and the bench very strong and then take it up from there and go down to further and further other products. Laxmi’s intention is to increase the margins overall as a company.
18. The first phase of fluoro the speciality segment will involve some building blocks but the company will also be getting into the downstreams of those building blocks.

19. In the last couple of months the prices of acetic acid have declined quite a bit.
Regarding acetic acid the overall global demand and supply has undergone change. Demand has been slightly weaker and therefore the acetic acid prices have been correcting. Feedstock prices would have come down as well therefore that has happened globally.
20. Laxmi has set up a kilo lab where they have many customers essentially a miniature plant of the Italian plant in India and the company did this during covid because they couldn't get access to Italy. This allowed Laxmi to absorb technology, get the
people trained on that and as well as sample out to customers. Currently for various customers the sample is in various stages of approval and that's a process that has helped Laxmi to shorten the time.

21. Laxmi’s requirement for HF remains fairly small.
22. Acetic acid prices softening has helped the margin expansion in the AI business in Q1FY23 along with the fact that the company optimized purchasing locally Vs importing
23. Laxmi doesn't hold on to inventory raw material for a very long period of time. Longest inventory holding period is about 30 days.

24. Fluoro chemicals capex - 350 to 400 crores

25. Hopeful of capitalizing the entire SI plant by the end of this fiscal.
By the end of FY22 the company has spent about 152 crores and in this quarter the company has spent about 30 crores so around 182 crores has been spent. There is a balance of 120-150 crores more to be spent.
26. AI business would be 30% more asset turnover than the SI business given that there is no capex in the AI business apart from debottlenecking.
27. Because FI is a greenfield site the asset turnover would be a little lower and as the company is able to add more and more blocks that's when it significantly improves. Asset turn would be below 1 in the beginning for FI.
SI asset turnover is much above 1 because its a brownfield expansion.

Register to model Portfolio to watch detailed analysis on chemical and pharma stocks
Link : valueeducator.com/advisory/

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Value Educator

Value Educator Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @ValueEducator

Jul 30
#PiramalPharma Q3 Concall highlights 💊💊

Like & Share for better reach !

The demerger of Piramal enterprises is expected to be completed by Q3 FY2023

Q1 FY2023 Performance

Pharma Revenues Image
CDMO :
Q1 FY23 Revenue grew 8% YoY
Despite the global challenges in biotech funding, company is witnessing high RFP activity from existing and new clients according the management

Major Issues in the CDMO business
1. Significant attrition at overseas site during pandemic Image
2. Customer order deferrals
This is coupled with several execution and supply chain challenges

Capacity expansion in niche capabilities ( Previously Planned CAPEX: US$157mn growth capex underway):

- Inaugurated new API plant in Aurora, Canada
- Upgraded Oral Solid Dose
Read 13 tweets
Jul 28
#LaurusLabs Q1 FY23 concall highlights 💊💊

Like & Retweet for better reach !

1. Revenue for the quarter was ₹1539 Cr (20% growth YoY). The EBITDA margin was 29.5% for the quarter despite inflationary pressures.

2. They saw significant growth in their CDMO business
(196% growth YoY, 60% growth QoQ) which helped offset the muted performance of the ARV business.

3. RM prices remain elevated due to the geopolitical situation and the Covid lockdown in China. But they are expecting gradual decrease in RM prices during the year
4. They are confident of achieving the aspirational target of $1 billion in revenue which will be supported by several approvals during the year.

5. With respect to their ARV business in LMIC markets - the demand was soft but the major issue is that the pricing has been largely
Read 18 tweets
Jul 28
Detailed Thread on #apollopipes

Like & Retweet for better reach !

Topics Covered :

1. Company overview
2. Management
3. APL Apollo Tubes Ltd
4. Products
5. Margins
6. Plants
7. Distribution
8. Marketing
9. Revenue mix
10. Company’s Key Focus Areas
11. Future Capex
12. Financials
13. EBITDA Margins

1. Company Overview
Apollo Pipes is among the top 10 leading piping solution providing companies in India. Headquartered at Delhi, the Company enjoys strong brand equity in the domestic markets. With more than three decades of experience
in the Indian PVC Pipe Market, Apollo Pipes holds a strong reputation for high quality products and an extensive distribution network.
Read 36 tweets
Jul 28
#SuvenPharma Annual Report 2022 Key Takeaways 💊💊

Like & retweet for better reach !

1. They had a great performance in FY22. They had initially given a guidance of 10-15% growth in revenues and ended the year with 47% growth in topline.
The EBITDA margin was above 50% for the year despite inflationary pressure.

2. A major part of the growth came from the Specialty Chemicals segment. Revenue for this vertical grew by 51% YoY due to increased volumes. They saw good volume offtake for the 1st commercialized
molecule which is now generic. But the partner developed a robust life cycle management which generated good volumes.

3. There was also a commercialization of a 3rd molecule in this segment which helped increase volumes. They currently have 1 more molecule in development
Read 16 tweets
Jul 27
#apollopipes Q1 23 Concall Highlights

Like & Retweet for better reach !

1. Revenue in Q1 FY23 grew by 59% to 218.9 crs from 137.6 crs in Q1 Fy22 but down 11.5% sequentially from 247.5 crs. Volume grew 38% to 14406MT from 10200MT in Q1 FY22.
2. EBITDA was 20.0 crs as against 17.4 crs y-o-y but dropped from 28.4 cr in previous quarter. Margin also dropped to 9.2% from 11.5% q-o-q. EBITDA per tonne dropped to 14000 per tonne from 17500 per tonne. This drop was because of drop in pvc prices.
Company is targeting 20000 EBITDA per tonne in next two years.
3. Growth looks robust y-o-y basis because of low base last year but weak sequentially because
of massive correction in PVC prices. This created uncertainty among channel partners who went into destocking mode.
Read 12 tweets
Jul 27
#FinolexPipes Q1 23 Concall Highlights

Like and Retweet for better reach !

1. Total revenue registered a y-o-y growth of 23% to Rs. 1,190 Cr from Rs. 965 Cr, but down
25% q-o-q from 1595 cr.
2. Degrowth in EBITDA was 40% to 126cr in Q1 23 from 210 cr in Q1 22. Margins also dropped
to 11% from 22%. Reasons for fall in EBITDA were because of Weak agri demand and
inventory losses due to fall in PVC prices.
3. PVC Pipes & Fittings volume grew 29% y-o-y to 71,960 MT and for PVC Resin volume registered a y-o-y growth of 25% to 62,746 MT. Volume for CPVC was 3600 MT with revenue of about 150 crores.
Read 13 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us on Twitter!

:(